TherapeuticsMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 07:31 am EDT
Share
TherapeuticsMD, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.437 million compared to USD 0.348 million a year ago. Net loss was USD 2.41 million compared to net income of USD 112.28 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 1.7 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 1.7 a year ago. Basic loss per share was USD 0.24 compared to basic earnings per share of USD 12.83 a year ago. Diluted loss per share was USD 0.24 compared to diluted earnings per share of USD 12.83 a year ago.
For the six months, revenue was USD 0.853 million compared to USD 1.04 million a year ago. Net loss was USD 6.02 million compared to net income of USD 63.26 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 3.77 a year ago. Diluted loss per share from continuing operations was USD 0.47 compared to USD 3.77 a year ago. Basic loss per share was USD 0.6 compared to basic earnings per share of USD 7.29 a year ago. Diluted loss per share was USD 0.6 compared to diluted earnings per share of USD 7.29 a year ago.
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).